Biosimilar Inspection Modernization Act of 2025

# Biosimilar Inspection Modernization Act of 2025 - Summary **What It Does:** This bill would modernize how the FDA inspects biosimilar drugs—medications that are highly similar copies of expensive biologic drugs already approved by the FDA. The legislation aims to update inspection procedures and requirements for biosimilar manufacturers to reflect current scientific understanding and manufacturing practices. **Who It Affects:** The bill would primarily impact pharmaceutical companies that manufacture biosimilars, the FDA (which conducts inspections), and patients who use these medications.

Biosimilars can be more affordable alternatives to original biologic drugs, so changes to their approval and inspection processes could eventually affect medication costs and availability for patients. **Current Status:** As of now, the bill (S 3510) is in committee and has not yet been voted on by the full Senate. Limited details are publicly available about specific provisions, so the exact nature of the proposed modernizations has not been disclosed in standard legislative summaries.